HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.